Skip to main content
Premium Trial:

Request an Annual Quote

23andMe Raises $82.5M in Private Financing

NEW YORK — 23andMe has raised $82.5 million through an equity sale, according to a filing late last week with the US Securities and Exchange Commission.

According to the filing, 23andMe offered a total of $85 million worth of equity.

The firm confirmed that the Series F round was led by Sequoia Capital and NewView Capital, which was reported yesterday by Bloomberg

In January, the Sunnyvale, California-based direct-to-consumer genetic test developer and ancestry information firm laid off about 100 of its employees — roughly 14 percent of its workforce at the time — amid a restructuring of its consumer business.

In mid-2018, 23andMe raised about $300 million in an equity offering. The year before, the company closed an approximately $250 million financing round led by Sequoia Capital.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.